Mildronate (Meldonium Dihydrate)

Meldonium inhibits the enzyme γ‑butyrobetaine hydroxylase, decreasing the synthesis of carnitine. This shifts cardiac energy metabolism from fatty‑acid oxidation toward glucose oxidation, which requires less oxygen, thereby improving the efficiency of heart muscle during ischemic conditions.

The dosage of Mildronate is determined by the prescribing physician based on the individual patient's clinical condition, severity of disease, and response to therapy. Specific dosing regimens are not provided here and should follow the prescriber's instructions.

Safety data for Meldonium in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Mildronate, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Mildronate differs from many anti‑ischemic drugs by targeting myocardial metabolism rather than solely affecting coronary blood flow. While agents like nitrates or beta‑blockers reduce workload or dilate vessels, Meldonium improves cellular energy efficiency, offering a complementary mechanism of action.

Mildronate should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to maintain its stability and potency.

Mildronate is supplied as an injectable solution for intravenous administration. It is given by a healthcare professional under aseptic conditions, typically as a slow infusion according to the prescriber's dosing schedule.

Serious adverse events reported with Mildronate include arrhythmias, severe hypotension, allergic reactions such as anaphylaxis, significant liver enzyme elevations, renal impairment and, rarely, myocardial infarction. Patients should be monitored closely for these conditions.

Mildronate is contraindicated in patients with known hypersensitivity to meldonium or any of its excipients. Caution is advised for individuals with severe hepatic or renal dysfunction, uncontrolled hypertension, or those receiving interacting metabolic modulators.